Purpose of review: Intracranial hemorrhage remains one of the most feared acute neurological emergencies. However, apart from the acute management, secondary risk factor management and prevention of ischemic events remains ambiguous. We present a thorough review of the current data available regarding management of antithrombotics after intracranial hemorrhage. Recent findings: The most robust evidence comes from the investigators of the RESTART trial which reassured the safety of resuming antiplatelet therapy after ICH, namely in patients with prior indication and treatment with antithrombotics. Summary: We conclude that based on available data, the risk of recurrent ICH is probably too small to exceed the found benefits of antiplatelet therapy in the secondary prevention of ischemic vascular disease.
|Original language||English (US)|
|Journal||Current Treatment Options in Cardiovascular Medicine|
|State||Published - Dec 1 2019|
- Intracranial hemorrhage
- Ischemic stroke
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine